What Happens When Medicare Bridge Ends? Scenario Planning for 2028
Prices verified May 2026 · Updated for mid-2026
⚡ TL;DR — OUR VERDICT
Nobody knows what happens after December 2027. The BALANCE Model is delayed, Congress hasn't acted, and insurance plans are hesitant. Patients on the Bridge should start building a backup plan now — identify a compounded provider, research manufacturer programs, and understand their options before the clock runs out.
The Timeline Problem
The Medicare GLP-1 Bridge runs July 2026 through December 2027. The original plan was for CMS's BALANCE Model to take over in Medicare Part D starting January 2027 — but not enough insurance plans signed on. The Bridge was extended from 6 months to 18 months as a stopgap.
As of May 2026, there is no confirmed successor program.
Scenario 1: BALANCE Model Launches (Optimistic)
CMS finds enough participating Part D plans and launches BALANCE in 2028. Patients transition from Bridge to ongoing Part D coverage with negotiated GLP-1 pricing. Cost to patients would depend on plan design — possibly $50–$100/month with normal Part D cost-sharing rules.
Probability: Uncertain. Insurance industry resistance is well-documented.
Scenario 2: Bridge Extended Again
CMS extends the Bridge for another 12–18 months while continuing to negotiate with Part D plans. Patients continue at $50/month. This is the path of least resistance politically.
Probability: Moderate. CMS has already extended once.
Scenario 3: Congressional Action
Congress passes legislation adding GLP-1 coverage for obesity to Medicare Part D permanently. The Anti-Obesity Medication Treatment (AOMT) Act or similar legislation has bipartisan support in concept, but cost estimates ($50–$100 billion over 10 years) create political hurdles.
Probability: Low in the short term. Possible in 2028–2029 election cycle.
Scenario 4: Nothing Replaces It (Worst Case)
Bridge ends, BALANCE doesn't launch, Congress doesn't act. Medicare patients who were on $50/month brand-name GLP-1s face a return to retail pricing ($800–$1,300/month). Most will stop treatment. Weight regain follows.
Probability: Real enough to plan for.
Your Contingency Plan
- Research compounded providers now: Know who you'd switch to and at what price. GobyMeds at $99/month and Embody at $149+ are the current leaders
- Check manufacturer programs: NovoCare (Wegovy) and LillyDirect (Zepbound/Foundayo) may offer Medicare-specific savings programs post-Bridge
- Consider establishing a compounded relationship before the Bridge ends: Having an active patient relationship makes transition smoother
- Talk to your doctor about dose optimization: If you can maintain weight loss at a lower dose, the cost impact of any transition is reduced
Backup Options to Research Now
GobyMeds
$99/mo
Compounded semaglutide $99/mo. No expiration date, no government program dependency.
Compare →Paid link · Compounded medications are not FDA-approved
Embody
$149 first month
Compounded semaglutide $149 first month. Established provider with clinical support.
Compare →Paid link · Compounded medications are not FDA-approved
Sesame Care
From $29/visit
Brand-name access from $29/visit if manufacturer programs materialize.
Compare →Paid link · Compounded medications are not FDA-approved
Compare All 26 Providers
Side-by-side pricing, formats, and what's included.
See the Full Comparison →